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Abstract: 
Background: HDL exerts endothelial-protective effects via stimulation of endothelial cell 
NO production. This function is impaired in patients with cardiovascular disease. Studies 
demonstrated that exercise training (ET) has protective effects on endothelial function. Aim 
of this study was to evaluate HDL function in patients with chronic heart failure (CHF), the 
impact of ET and the respective molecular pathways. 
Methods: HDL was isolated from 8 healthy controls (HDLhealthy) before and after ET, , 8 
patients with CHF-NYHA-II (HDLNYHA-II), and 8 patients with CHF-NYHA-IIIB (HDLNYHA-IIIb) 
before and after ET. Endothelial cells (EC) were incubated with HDL and phosphorylation 
of eNOS-Ser1177, eNOS-Thr495, PKC-ßII-Ser660 and p70S6K-Ser411 was evaluated. HDL-
bound malondialdehyde and HDL-induced NO production by EC was quantified. The 
proteome of HDL particles were investigated by shotgun LC-MS/MS. Endothelial function 
was assessed by flow-mediated dilatation (FMD). 
Results: Incubation of ECs with HDLNYHA-IIIb reduced phosphorylation of eNOS-Ser
1177, 
whereas phosphorylation at eNOS-Thr495 increased when compared to HDLhealthy. This 
was associated with lower NO production of ECs incubated with HDLNYHA-IIIb. In addition an 
elevated activation of p70S6K, PKC-ßII by HDLNYHA-IIIb, and a higher amount of 
malondialdehyde bound to HDLNYHA-IIIb was measured. 
ET of healthy individuals had no effect on HDL function, wheres ET of CHF-NYHA-IIIB 
significantly improved HDL function. A correlation between changes in HDL-induced NO 
production and FMD improvement by ET was evident. 
Discussion: These results demonstrate that HDL-function is significantly impaired in CHF 
and that ET improved the vascular effects of HDL. This may be one mechanism how ET 
exerts its beneficial effects in CHF. 
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Introduction 
An abnormality in endothelium-dependent vasodilatation is a key phenomenon in patients 
with chronic heart failure (CHF). Numerous animal 1,2 and human 3,4 studies demonstrated 
a significant improvement in endothelium-dependent relaxation by exercise training (ET). 
An important factor responsible for this improvement is the increase in the bioavailability of 
nitric oxide (NO). Studies using cultured endothelial cells 5,6 or vessel tissue specimens 
obtained from trained animals 7 or humans 8 clearly documented that an increase in shear 
stress resulted in activation of endothelial nitric oxide synthase (eNOS), either by 
increased expression 9 or an activation by phosphorylation 8, and a reduced production of 
reactive oxygen species competing for NO 10.  
High-density lipoprotein (HDL) levels above 40-60 mg/dl have been proposed as strong 
independent predictor of lower coronary artery disease risk 11,12,13. Besides promotion of 
reverse cholesterol transport, HDL has been found to exert important anti-atherogenic 
effects by stimulation of endothelial cell NO production and endothelial repair as well as 
anti-inflammatory and anti-oxidant effects 14,15,16,17,18,19. In recent studies it became evident 
that the functional properties of HDL with respect to stimulation of NO production is 
significantly impaired in patients with diabetes 20, coronary artery disease 21, and primary 
antiphospholipid syndrome 22. Mechanistically it is proposed that in these patients 
malondialdehyde-modified HDL triggers the activation of PKC-ßII, thereby reducing eNOS-
dependent NO production 21. Based on these findings on the functional importance of HDL 
in influencing endothelial function, the therapeutic approach targeting HDL is beginning to 
shift towards improving HDL function rather than just increasing its concentration 
(reviewed in 23).This view is further supported by the recently published dal-OUTCOMES 
trail, documenting that just raising the HDL level does not reduce the risk of recurrent 
cardiovascular events 24. 
To critically assess the relation between disease severity of patients with CHF and HDL 
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function, we isolated HDL from healthy, CHF patients in NYHA class II and IIIB and 
determined its ability to stimulate eNOS activation and thereby NO production. To study 
the impact of ET on HDL function, HDL was additionally isolated from healthy individuals 
and NYHA-IIIb patients after an ET program and its stimulating effect on eNOS 
phosphorylation and NO production was evaluated.  
 
 
Methods 
 
Patient population and blood sampling 
Eight healthy control subjects (HS) with normal systolic LV function (>55%), without signs 
or symptoms of CHF and without evidence of coronary artery disease during coronary 
angiography were included into the study. The HS performed an ET program as outlined 
below for 4 weeks. In addition 8 patients with CHF (LVEF <40%) in NYHA class II and 8 
CHF patients in NYHA class IIIb were recruited. Patients in NYHA IIIb were assigned to a 
12 week ET program as outlined below. 
Blood was collected from all subjects when entering the study and when finishing the ET 
program (only healthy and NYHA IIIb subjects). Serum was prepared by ultracentrifugation 
(10 min at 3000 x g at 4°C) and stored at -80°C until used. 
 
Training protocol of patients in NYHA IIIb 
The initial phase of the exercise program was supervised and performed in-hospital. 
During the first 3 weeks, patients exercised 3 to 6 times daily for 5 to 20 minutes on a 
bicycle ergometer adjusted to the work load at which 50% of maximum oxygen uptake 
(VO2max) was reached. Before discharge from the hospital, symptom-limited 
spiroergometry was performed again to determine the training target heart rate for home 
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based training (defined as the heart rate reached at 60% of VO2max). On discharge, 
patients were provided with bicycle ergometers for home based ET. They were 
encouraged to exercise close to their target heart rate for 20 to 30 minutes daily for a 
period of 12 weeks and were expected to participate in 1 supervised group training 
session for 60 minutes every week consisting of walking, calisthenics, and noncompetitive 
ball games.  
 
Measurement of endothelial function 
Flow-mediated dilatation (FMD) of the radial artery was measured using a high-resolution 
ultrasound scanning echo-tracking angiometer (NIUS 02, Asulab Research Laboratory, 
Neuchatel, Switzerland) as described previously 25,26. 
 
Isolation of HDL 
HDL was isolated from serum by sequential density ultracentrifugation (d = 1.006 – 1.21 
g/ml) as recently described in detail. 20,21 Quality of isolated HDL was evaluated by 
polyacrylamid gel electrophoresis followed by coomassie blue staining.  
 
Cell culture and incubation with isolated HDL 
Human aortic endothelial cells (HAEC, Cell Systems Biotechnology, Troisdorf, Germany) 
were cultured in EGM-2 cell culture medium (Lonza, Wlkersville MD, USA) until 80 to 90% 
confluence. Cells were incubated for 0, 5, 10, 15, 30 or 60 min with 50 µg/ml isolated HDL. 
To elucidate signaling pathways cells were pretreated (1h prior HDL stimulation) with 
specific inhibitors like rapamycin (Santa Cruz, Heidelberg, Germany; 20 nmol/l) to inhibit 
p70S6K or CG53353 (Merck Chemicals, Nottingham, UK; 2 µmol/L) to inhibit PKC-ßII. 
Thereafter, cells were harvested with ice cold lysis buffer (50 mmol/L Tris-HCl pH 7.4, 1% 
NP-40, 0.25% Na-deoxycholate, 150 mmol/L NaCl, 1 mmol/L EDTA, 0.1% Triton X-100, 
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0.2% SDS) containing protease inhibitor mix M (Serva, Heidelberg, Germany) as well as 
phosphatase inhibitors (Phosphatase inhibitor mix II, Serva, Heidelberg, Germany). 
Protein concentration was determined using BSA as standard (BCA method, Pierce, 
Rockford IL, USA). 
 
Western blot analysis 
Ten µg of total protein was separated on a denaturing polyacrylamid gel and transferred to 
a PVDF membrane. To detect specific proteins the following antibodies were applied: anti-
endothelial nitric oxide synthase (eNOS) (Santa Cruz, Heidelberg, Germany), anti 
phospho-eNOS-Ser1177, anti phospho-eNOS-Thr495 (both BD Bioscience, Heidelberg, 
Germany), anti-PKC-ßII, anti-phospho PKC-ßII-Ser660, anti-p70S6K, anti-phospho 
p70S6K-Ser411 (all Santa Cruz, Heidelberg, Germany). All samples were analyzed in 
triplicate.  
 
Measurement of endothelial cell NO production by ESR spectroscopy 
HAEC cell were incubated with HDL (50 µg/ml) for 60 min. Nitric oxide production in 
human aortic endothelial cells (HAECs) was measured by ESR spectroscopy using the 
spin-probe colloid Fe(DETC)2 as recently described 
20,21. 
 
Measurement of Pon1 enzymatic activity 
Paraoxonase activity of HDL-associated paraoxonase-1 (PON1) was measured by 
spectrophotometry using paraoxon as substrate. 21 
 
Quantification of protein-bound malondialdehyd in HDL 
Free and protein-bound malondialdehyde (MDA) in HDL was detected by a commercially 
available lipid peroxidation assay kit (ALDetect, Enzo Life Sciences) as recently described. 
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21  
 
Measurement of plasma oxidative capacity 
Oxidative capacity was determined in plasma samples from all participants using a 
commercial available quantification kit (PerOx (KC5100) kit, Immundiagnostik, Bensheim, 
Germany). Measurements were performed in duplicate according to the manufactures 
recommendations.  
 
NanoLC-MS/MS analysis 
The proteome of isolated HDL particles were investigated by shotgun LC-MS/MS (for 
detailed description see online supplement). 
 
Statistical Analysis 
SPSS version 16.0 (SPSS Inc, Chicago, Ill) was used for all of the analyses. Data are 
expressed as mean±SEM. Comparisons among groups were tested with ANOVA. When 
data were not normally distributed or the variance was not equal, the Kruskal-Wallis 
nonparametric test was used. A value of p<0.05 was considered statistically significant. All 
of the measurements were made by investigators blinded to the treatment group. 
 
 8 
Results 
Patient characteristics and follow-up after exercise training 
The baseline values for all individuals included into the study are depicted in Table 1.  
As expected the healthy individuals significantly differed from patients with chronic heart 
failure with respect to LV ejection fraction, maximal oxygen consumption and medication. 
No difference was observed between the three groups comparing age, BMI, arterial 
hypertension and diabetes mellitus. None of the participants was active smoking. 
Analyzing the lipid profile, only a significant lower HDL concentration was evident in CHF 
patients in NYHA class IIIb when compared to healthy individuals. 
The exercise program of 12 weeks in NYHA class IIIb patients led to an increase of 
VO2max (14.3±1.2 to 17.4±1.6 ml/kg/min; p<0.05) and left ventricular ejections fraction 
(24±2 to 34±2 %; p<0.05). With respect to the lipid profile no change after 12 weeks of ET 
was evident.  
 
HDL-mediated eNOS phosphorylation and NO production – impact of exercise 
training 
Incubating HAEC with HDLhealthy the phosphorylation of eNOS at position Ser
1177 was 
increased 5.0±0.5 fold vs. unstimulated cells. This stimulation of eNOS-Ser1177 was lower 
with HDLNYHA-II (3.7±1.1 fold vs. unstimulated cells; p=NS vs. healthy controls), reaching 
significance in CHF patients in NYHA class IIIb (1.8±0.4 fold vs. unstimulated cells; p<0.05 
vs. healthy controls) (Figure 1A). Analyzing the eNOS phosphorylation at position Thr495, 
HDLNYHA-IIIb stimulated the phosphorylation significantly more than HDLhealthy (NYHA IIIb: 
3.3±0.4 fold vs. unstimulated cells; NYHA II: 2.6±0.5 fold vs. unstimulated cells; healthy 
controls: 1.5±0.4 fold vs. unstimulated cells; p<0.05 NYHA IIIb vs. healthy controls). 
(Figure 1B). These differences in HDL-mediated eNOS phosphorylation capacity between 
the groups are also evident when measuring the HDL-induced NO production of 
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endothelial cells (Figure 2). 
Comparing the functional properties of HDLNYHA-IIIb before and after an exercise program 
revealed a significant improvement in phosphorylation of eNOS at position Ser1177 (begin: 
1.8±0.4 fold vs. unstimulated cells; end: 4.4±0.9 fold vs. unstimulated cells; p<0.05) 
(Figure 1A), a significant reduction in phosphorylating eNOS at position Thr495 (begin: 
3.3±1.0 fold vs. unstimulated cells; end: 2.1±0.4 fold vs. unstimulated cells; p<0.05) 
(Figure 1B), and a significant higher production of NO in endothelial cells (begin: -1.0±3.3 
% increase versus buffer treated cells; end: 19.4±7.5 % increase versus buffer treated 
cells; p<0.01) (Figure 2). No significant impact of exercise training was observed in the 
healthy control group with respect to HDL-mediated eNOS-Serr1177 phosphorylation (begin: 
5.0±0.5 fold vs. unstimulated cells; end: 4.0±1.0 fold vs. unstimulated cells; p=NS), eNOS-
Thr495 phosphorylation (begin: 1.5±0.4 fold vs. unstimulated cells; end: 1.5±0.3 fold vs. 
unstimulated cells; p=NS) (Figure 1A and B) and NO production (Figure 2).  
 
HDL-mediated PKC-ßIISer660 phosphorylation 
Incubation of HAEC with HDLhealthy resulted in a 1.4±0.3 fold increase in PKC-ßII 
phosphorylation at position Ser660 when compared to unstimulated cells. This ability to 
stimulated PKC-ßII phosphorylation is increased with increasing severity of CHF (NYHA II: 
1.8±1.1 fold vs. unstimulated cells, NYHA IIIb: 2.2±0.7 fold vs. unstimulated cells; p<0.05 
NYHA IIIb vs. healthy) (Figure 3A). Performing an exercise program in patients with CHF 
NYHA class IIIb significantly reduced the ability of HDL to phosphorylate PKC-ßII (begin: 
2.2±0.7 vs. end: 1.4±0.2 fold vs. unstimulated cells; p<0.05) (Figure 3A). No impact of ET 
on HDL-induced phosphorylation of PKC-ßII was observed in the healthy controls (begin: 
1.4 ±0.3 vs. end: 1.6±0.2 fold vs. unstimulated cells; p=NS) (Figure 3A).  
To evaluate the importance of PKC-ßII activation for HDL-induced eNOS-phosphorylation, 
the HDLNYHA-IIIb induced eNOS phosphorylation at Ser
1177 and Thr495 was measured in the 
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absence or presence of a specific PKC-ßII inhibitor (CG53353). As shown in Figure 3B the 
inhibition of PKC-ßII prevented the HDL-induced phosphorylation at eNOS-Thr495 without 
having any influence on eNOS-Ser1177 phosphorylation.  
 
HDL-mediated p70S6K-Ser411 phosphorylation 
Incubation of HAEC with HDLhealthy resulted in a 1.5±0.2 fold increase in p70S6K 
phosphorylation at position Ser411 when compared to unstimulated cells. This ability to 
stimulated p70S6K phosphorylation is increased with increasing severity of CHF (NYHA II: 
1.9±0.4 fold vs. unstimulated cells, NYHA IIIb: 3.1±0.7 fold vs. unstimulated cells; p<0.05 
NYHA IIIb vs. healthy) (Figure 4A). Performing an exercise program in patients with CHF 
NYHA class IIIb significantly reduced the ability of HDL to phosphorylate PKC-ßII (begin: 
3.1±0.7 vs. end: 1.4±0.1 fold vs. unstimulated cells; p<0.01) (Figure 4A). No impact of ET 
on HDL-induced phosphorylation of PKC-ßII was observed in the healthy controls (begin: 
1.5 ±0.2 vs. end: 1.7±0.2 fold vs. unstimulated cells; p=NS) (Figure 4A).  
Blocking PKC-ßII activation by CG53353 resulted in an inhibition of HDLNYHA-IIIb-induced 
phosphorylation of p70S6K at Ser411 (Figure 4B). In addition, blocking p70S6K activation 
by rapamycin prevented the HDLNYHA-IIIb-induced phosphorylation of eNOS at Thr
495 
without influencing eNOS phosphorylation at Ser1177 (Figure 4 C/D).  
 
Malondialdehyde bound to HDL 
HDL-bound MDA was significantly increase in HDLNYHA-IIIb when compared to HDLhealthy 
(healthy: 0.39±0.09 nmol/mg HDL; NYHA II: 0.64±0.09 nmol/mg HDL; NYHA IIIb: 
1.13±0.10 nmol/mg HDL; p<0.001 healthy vs. NYHA IIIb, p<0.05 NYHA II vs. NYHA IIIb) 
(Figure 5A). After finishing an ET program the amount of HDL-bound MDA was 
significantly reduced by 27.4±6.1% in CHF-NYHA-IIIb, whereas no change was observed 
in healthy controls (Figure 5B). 
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Pon-1 enzyme activity and total lipid peroxides 
Measuring the paraoxonase enzymatic activity of PON-1 associated with the isolated HDL, 
a significant decrease in HDLNYHA-IIIb was evident when compared to HDLhealthy (Figure 5C). 
It also became evident, that in the patients in NYHA IIIb assigned to an exercise 
intervention program no change in paraoxonase (Figure 5C).  
Evaluating circulating total lipid peroxides (LPO) as measure for the oxidative status, a 
significant increase was obvious in the plasma of CHF NYHA IIIb patients when compared 
to healthy controls (healthy: 151±41 vs. NYHA-IIIb: 351±71 µmol/L; p<0.05). Furthermore, 
the ET intervention let to a significant reduction of LPO (Begin NYHA-IIIb: 351±71 vs. end: 
NYHA-IIIb: 210±54 µmol/L; p<0.05) (Figure 5D). No impact of ET on LPO was evident in 
healthy controls (Figure 5D).  
 
Correlation between HDL and endothelial function 
To investigate if the exercise-induced change in HDL function observed in CHF NYHA IIIb 
patients has some influence on endothelial function, a correlation analysis between the 
change in HDL function and the observed change in endothelial function was performed. A 
significant correlation was evident between the change in HDL-induced eNOS-Ser1177 
phosphorylation (r=0.81, p<0.05; see supplementary Figure 1A) or the absolute change in 
HDL-induced NO production (r=0.78, p<0.05; see supplementary Figure 1B) and the 
change in endothelial function.  
 
Proteome analysis of HDL particles 
In the complete LC-MS/MS dataset, 134 proteins from 709 distinct peptides were identified 
using the Mascot algorithm; 65 proteins with at least one unique peptide per protein and 
69 proteins with at least two peptides per protein were identified. 
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A Venn's four-set diagram using ellipses shows common and unique proteins between the 
analyzed groups (Figure 6A). Only a very small proportion of proteins were identified 
uniquely for one treatment group. The proteins identified in all groups (n=75) were further 
used for direct label free quantitation utilizing peptide intensities as indicator for protein 
abundance. A principal component analysis (PCA) plot as indicator of the variance in the 
dataset (n=134 proteins) is shown in Figure 6B. Each point represents one LC-MS/MS run 
of one subject. The plot displays the first two principal components that accounts for about 
30% of the global variance. A clear distinction of the HDL proteome was observed between 
the healthy controls (pre and post intervention) and CHF-NYHA-IIIb patients (pre and post 
intervention). However ET did not result in a clear separation of the HDL proteome in 
healthy controls (Beg. Vs. end) and CHF-NYHA-IIIb patients (Beg. vs. end; Figure 6B).  
To define significantly abundant proteins between healthy controls and CHF-NYHA-IIIb 
patients a independent T-test as statistical analysis was applied. A Volcano plot shows the 
significance versus effect size-change on the y- and x-axes, respectively to quickly 
visualize the most meaningful changes (Figure 6C/D). The comparison of controls and 
NYHA patients at study begin (Figure 6C) indicated 13 statistically relevant proteins shown 
as red marked spots. After intervention, 17 proteins were differentially regulated between 
controls and NYHA patients (Figure 6D, Table 1). A dependent (paired) T-Test was 
performed to identify significant relevant proteins within the control and the patients groups 
influenced by ET. However, only one protein (Apolioprotein C-II (APOC2) with a minor 
effect size (effect size of 0.19 is means 1.15 fold change) was statistically differential in the 
healthy control group (Table 1). Additionally, we identified protein groups that were not 
previously identified in HDL particles, such as beta-Ala-His dipeptidase (CNDP1), 
pulmonary surfactant-associated protein B (SFTPB) or leucine-rich repeat-containing 
protein 15 (LRRC15) 
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Discussion 
HDL shows many anti-atherosclerotic properties, including reverse cholesterol transport, 
decreasing oxidation of LDL and the expression of adhesion molecules (for review see 19), 
stimulating eNOS-dependent NO production 14,27,28 and mediation of endothelial repair 
mechanisms 29,30,31. In recent years it became evident that not only the quantity but also 
the functional capacity of HDL is important for influencing the risk of cardiovascular 
disease 32. Therefore, strategies are developed to increase HDL quantity and function 23. 
ET is an accepted intervention strategy in patients with systolic heart failure 33 and part of 
the molecular mechanisms behind the beneficial effect of ET have been described (for a 
detailed review see 34). With respect to functional properties of HDL in patients with chronic 
heart failure and the impact of ET several findings emerge from the present study. First, 
the functional capacity of HDL to increase NO production in endothelial cells via 
modulation of eNOS phosphorylation is impaired in patients with chronic heart failure. This 
functional incompetence is gradually increasing with disease severity. Second, in CHF 
patients the amount of MDA bound to HDL is significantly elevated and the activation of 
PKC-ßII/p70S6K by HDLNYHA-IIIb is significantly increased when compared to HDLhealthy. 
Third, ET in CHF patients in NYHA IIIb for 12 weeks significantly restored the functional 
capacity of HDL as well as the amount of MDA bound to HDL and the HDL-mediated 
activation of PKC-ßII/p70S6K. The ET-induced change in HDL function significantly 
correlates with an improved endothelial function. Fourth, proteom analysis of the HDL 
particle revealed a clear distinction between HDL isolated from healthy controls and CHF –
NYHA-IIIb patients. No significant impact of ET on the overall composition of the HDL 
particle was evident. 
 
These findings suggest, that ET has a positive effect on HDL function with respect to NO 
generation, and this might be one pathway how ET improves endothelial function in 
 14 
patients with CHF.  
 
Chronic heart failure and the ability of HDL to regulate NO production  
Experimental and clinical studies have suggested that eNOS-derived NO is a crucial 
determinant of vascular homeostasis, and reduced bioavailability of NO plays an important 
role in the development and progression of atherosclerosis 35. Especially in patients with 
coronary artery disease the amount of bioavailable NO is significantly reduced due to 
lower expression of eNOS 8 or an increased concentration of reactive oxygen species 
(ROS) 10. But also patients with chronic heart failure irrespective of atherosclerotic etiology 
are characterized by endothelial dysfunction as a result of increased oxidative stress and 
reduced NO bioavailability 36.  
The activity of eNOS is regulated by intracellular calcium concentration, by modulating the 
protein concentration per se or by phosphorylation at specific residues via activation of 
protein kinase B (Akt) or protein kinase A (PKA) (for detailed review see 37). Besides the 
activation of eNOS by shear stress or agonists like acetylcholine, bradykinin, or vascular 
endothelial growth factor (VEGF), HDL also has the potency to activate eNOS by binding 
to the scavenger receptor-B1 14. In the present study we described for the first time that 
the capacity of HDL isolated from CHF patients to phosphorylate eNOS and generate NO 
is significantly impaired. This reduced ability of HDL to stimulate eNOS activity (increased 
phosphorylation at position Thr495 and reduced phosphorylation at position Ser1177) even 
seems to be related to disease severity, since the most relevant impairment was seen in 
CHF patients in NYHA class IIIb followed by patients in NYHA II when compared to healthy 
controls. This loss in functional capacity goes along with a significant reduction in NO. This 
result is in good agreement with findings in other atherosclerotic disorders like primary 
antiphospholipid syndrome 22, diabetes 20, and patients with stable CAD or acute coronary 
syndrome 21. This functional reduction of HDL is on top of a quantitative reduction of HDL 
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which was noted in the patients described in the present study and in the current literature 
38, resulting in a lower anti-atherosclerotic effect of HDL.  
 
Impact of exercise training on HDL function 
ET has been proven to partially correct endothelial dysfunction in a variety of diseases (for 
review see 39). As molecular mechanisms restoration of NO bioavailability due to an 
increase in eNOS expression and Akt-mediated phosphorylation of eNOS at position 
Ser1177  and the reduction in ROS are discussed 8, 10. Using cultured human endothelial 
cells and HDLNYHA-IIIb isolated before and after an ET intervention program, we could 
clearly demonstrate an improvement in HDL function, measured as the capacity to 
phosphorylate eNOS at Ser1177 and Thr495, culminating in an increased NO production. The 
positive effect of ET on HDL function is in line with a study performed on overweight/obese 
men with cardiovascular risk factors 40. In that study a 21-day intervention program 
consisting of high-fiber low fat diet combined with an exercise program (daily treadmill 
walking, 45-60 min, 70-85% of maximal heart rate) resulted in a lower HDL inflammatory 
index. Unfortunately the authors did not analyze the individual effects, so it is not possible 
to differentiate which intervention, diet or ET, is responsible for the observed effect. Based 
on the results presented in this study one may speculate that the training induced increase 
in NO bioavailability and finally the improvement of endothelial function is partly due to an 
altered HDL function. This assumption is at least supported by the positive correlation 
between the exercise-induced change in HDL function (change in HDL mediated 
phosphorylation of eNOS or HDL-mediated NO production) and the change in endothelial 
function. This functional improvement of HDL by ET is realized without a change in total 
HDL concentration. This finding highlights to an important point, namely that the functional 
competence of HDL may be more important for regulating endothelial 
function/antitrombotic function than the absolute amount. 
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Possible molecular mechanisms  
As already described for HDL isolated from patients with stable coronary artery disease or 
an acute coronary syndrome 21, HDL obtained from NYHA IIIb patients significantly 
activated PKC-ßII and subsequently p70S6K via phosphorylation at Ser660 or Ser411 
respectively . Inhibition studies using either CG53353 or rapamycin clearly documented 
that the activation of p70S6K is downstream of PKC-ßII activation, and that the HDL 
mediated activation of this pathways influences mainly the phosphorylation of eNOS at the 
inhibitory site Thr495. Of note, this activation of the PKC-ßII pathway was significantly 
reduced in CHF-patients after an ET program. In addition, using either transgenic mice or 
endothelial cell culture it could be documented that activation of PKC-ßII in endothelial 
cells and vascular tissue inhibits Akt-dependent regulation of eNOS 41,42. A central question 
based on this observation is what discriminates HDL isolated from healthy controls and 
patients with CHF in NYHA IIIb in its ability to activate PKC-ßII/p70S6K? At least two 
possibilities should be discussed. First, a change in the overall protein composition of the 
HDL particle and second a secondary modification of the HDL particle. With respect to 
protein composition a clear distinction was evident between the healthy controls and CHF-
NYHA-IIIb patients. However ET did not result in a significant modification in the HDL 
proteome, despite an improved HDL-mediated NO production. Second, an other potential 
mechanism would be the modification of apolipoprotein A-1, the major HDL protein, by 
reactive intermediates. Indeed impaired HDL-function after modification by MDA or myristic 
acid could be documented 43,44,45. For example MDA modification of HDL decreased 
cholesterol efflux from cultured human fibroblasts 43 or rat liver endothelial cells 44. Notably, 
in the present study we have observed that a significant higher level of MDA is bound to 
HDLNYHA-IIIb in comparison to HDLhealthy and that a training intervention significantly reduced 
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the MDA amount bound to HDLNYHA-IIIb. Supported by in vitro studies 
21 it is reasonable to 
assume that the amount of MDA bound to HDL regulates the activation of PKC-ßII (higher 
activation of PKC-ßII in case more MDA is bound to HDL) and finally the activation of 
eNOS and NO generation. Since the modulation of HDL by MDA seems to play such a 
central role, the question arises which factors are regulating the amount of MDA bound to 
HDL, and are they influenced by ET? Paraoxonase (Pon), an enzyme which is associated 
with HDL, protects lipoproteins (HDL and LDL) from oxidative modification. It is speculated 
that a lower level of Pon activity in the serum is associated with an increased risk of 
atherosclerosis. Indeed, in obese subjects with a higher risk for cardiovascular disease, a 
lower Pon activity was measured 46. This relation between Pon activity and the risk for 
cardiovascular disease was confirm in recent clinical studies 47,48. In the present study Pon 
activity of HDLNYHA-IIIb was significantly decreased when compared to HDLhealthy. 
Unfortunately, ET had no effect on Pon activity. This is in accordance with a study 
performed in obese men, showing improved HDL inflammatory/anti-inflammatory 
properties after a lifestyle intervention (combination of diet and an exercise intervention) 
without changing Pon activity 40. Therefore, at the moment it remains unclear which 
mechanism beside Pon may be responsible for the ET-mediated reduction in MDA bound 
to HDL. Of note an influence of ET on the total oxidative capacity, measured as lipid 
peroxides in the patient plasma, was evident. Therefore one may speculate that ET 
reduces the oxidative load, and thereby reduced the amount of MDA bound to HDL. 
 
Study limitations 
Some limitations of the present study should be mentioned.  
First, only 8 patients or healthy individuals were included into each group. Nevertheless, 
the primary study goal was to investigate if HDL function in patients with CHF is altered 
and if this can be reversed by ET. Even with such a small number of individuals in each 
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group a significant impaired HDL function in NYHA IIIb was evident which could be 
improved by ET. In addition no data are available on the impact of ET in CHF-NYHA-class 
II patients.  
Second, it remains unclear which mechanism is responsible for the exercise-induced 
reduction of MDA bound to HDL. According to the data presented in this study the activity 
of the paraoxogenase is not altered by ET, and therefore can be excluded. On the other 
hand we could observe an exercise-induced reduction in lipid peroxidation which is a 
general measure for the oxidative load. So far, it remains unclear which enzymatic system 
is responsible for the observed reduction in oxidative stress.  
Third, at the moment we do not know, if the alterations in the HDL-proteome observed 
between HDLhealthy and HDLNYHA-IIIb have any causal relevance for HDL-mediated eNOS 
phosphorylation. To answer this questions further studies using site directed mutagenesis 
are warranted.  
Fourth, the results presented in the study are obtained in cell culture experiments using 
HDL isolated from frozen serum of different patient cohorts. Therefore, it has to be 
answered if this modulation of HDL also has an impact on endothelial function in vivo. At 
least the correlation detected between the improvement in endothelial function induced by 
ET measured in vivo and the HDL associated change in eNOS phosphorylation and NO 
generation measured in vitro implies that this is an important mechanism for the regulation 
of endothelial function in vivo. With respect to storage of the serum at -80°C and 
functionality, no data with respect to HDL-mediated eNOS phosphorylation are available. 
Nevertheless, in a recent study investigating the HDL-mediated cholesterol efflux, no 
difference was seen between HDL isolated from fresh serum or serum stored for up to two 
years 49. 
 
Conclusion 
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In summary, the reduced ability of HDL to stimulate endothelial NO production via 
activation of eNOS in patients with advanced chronic heart failure suggest a loss of this 
functional property of HDL. Of note an ET program in this patient cohort seems to partially 
correct this dysfunction. This may be one possible explanation for the beneficial effect of 
ET on endothelial function. The exercise-mediated effect on HDL function seems to be 
mediated via a reduction in MDA bound to HDL, leading finally to a lower activation of 
PKC-ßII resulting in a higher activation of eNOS and a higher synthesis of NO (Figure 7).  
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Figure Legends 
Figure 1: HAEC were incubated with HDL (50 µg/ml) isolated from healthy controls 
(healthy) at begin (Beg) and after performing an exercise training program (end), CHF 
patients in NYHA-II (NYHA II) and CHF patients in NYHA III at begin (Beg) and after 
finishing of an exercise training program (End) and the phosphorylation of eNOS at 
position Ser1177 (A) and Thr495 (B) was evaluated by western-blot analysis. To compensate 
for protein loading differences phosphorylation at the specific site was normalized to the 
non-phosphorylated form. For quantitative analysis the x-fold increase in eNOS 
phosphorylation of HDL incubated cells vs. untreated cells was determined. 
Representative examples of the western blots are depicted on top of the figure. Values are 
expressed as mean±SEM.  
 
Figure 2: Effect of HDL (50 µg/ml, 60 minutes, 37°C) from healthy controls (healthy) 
before (Beg) and after an exercise programme (end), CHF patients in NYHA-II (NYHA II) 
and CHF patients in NYHA III at begin (Beg) and after finishing of ET (End) on endothelial 
NO production as determined by ESR spectroscopy. Data are expressed as percent 
change versus buffer-treated cells. Values are expressed as mean±SEM.  
 
Figure 3: HAEC were incubated with HDL (50 µg/ml) isolated from healthy controls 
(healthy) at begin (beg) and after finishing an ET program (end), CHF patients in NYHA-II 
(NYHA II) and CHF patients in NYHA III at begin (Beg) and after finishing an ET program 
(end) and the phosphorylation of PKC-ßII at position Ser660 was evaluated by western-blot 
analysis (A). HAEC were incubated with HDL (50 µg/ml) isolated from CHF-NYHA-IIIb 
patient in the presence or absence of a PKC-ßII inhibitor (+/- CG53353) and the 
phosphorylation of eNOS-Ser1177 (B) and eNOS-Thr495 (C) was evaluated. To compensate 
for protein loading differences phosphorylation at the specific site was normalized to the 
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non-phosphorylated form. For quantitative analysis the x-fold increase in PKC-ßII 
phosphorylation of HDL incubated cells vs. untreated cells was determined. 
Representative examples of the western blots are depicted on top of the figure. Values are 
expressed as mean±SEM.  
 
Figure 4: HAEC were incubated with HDL (50 µg/ml) isolated from healthy controls 
(healthy) at begin (beg) and after finishing an ET program (end), CHF patients in NYHA-II 
(NYHA II) and CHF patients in NYHA III at begin (Beg) and after finishing an ET program 
(end) and the phosphorylation of p70S6K at position Ser411 was evaluated by western-blot 
analysis (A). HAEC were incubated with HDL (50 µg/ml) isolated from CHF-NYHA-IIIb 
patient in the presence or absence of a PKC-ßII inhibitor (+/- CG53353) (B) or the p70S6K 
inhibitor rapamycin (+/- rapamycin, C,D) and the phosphorylation of p70S6K-Ser411 (B) or 
the the phosphorylation of eNOS-Ser1177 (C) and eNOS-Thr495 (D) was evaluated 
respecively. To compensate for protein loading differences phosphorylation at the specific 
site was normalized to the non-phosphorylated form. For quantitative analysis the x-fold 
increase in PKC-ßII phosphorylation of HDL incubated cells vs. untreated cells was 
determined. Representative examples of the western blots are depicted on top of the 
figure. Values are expressed as mean±SEM. 
 
Figure 5: Quantification of protein-bound MDA in HDL isolated from healthy controls 
(healthy), CHF patients in NYHA-II (NYHA II) and CHF patients in NYHA III (A) as well as 
the change after performing an exercise training programme (B). Pon 1 paraoxonase 
activity was measured in HDL isolated from healthy controls (healthy) before (Beg) and 
after an ET program (end), CHF patients in NYHA-II (NYHA II) and CHF patients in NYHA 
III at begin (Beg) and after finishing an ET program (end) (C). In addition, the total amount 
lipid peroxides as measure for the oxidative load was quantified in the plasma of all study 
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participants (D). Values are expressed as mean±SEM. 
 
Figure 6: A schematic drawing depicting common and unique proteins between the 
analyzed groups (A). A principal component analysis plot to separate HDL from healthy 
and CHF-NYHA-IIIb as well as before (Beg) and after performing an exercise training 
program (end) (B). A Volcano plot shows the significance versus effect size-change to 
quickly visualize the most meaningful changes comparing HDLhealthy and HDLNYHA-IIIb at 
begin (C) and after the exercise training program (C).  
 
Figure 7: Hypothetical working model, how disease progression and ET influences HDL-
induced NO production. Disease progression leads to a higher amount of MDA bound to 
HDL, whereby PKC-ßII gets more and more activated. This activation leads to an inhibition 
of HDL-mediated NO production due to a reduced eNOS phosphorylation at eNOS-Ser1177 
and a higher phosphorylation at eNOS-Thr495. This process seems to be partial reversible 
by ET.  
Table 1: Clinical characteristics and cardiovascular medication 
 
 Healthy 
Begin (n=8) 
Healthy 
End (n=8) 
CHF NYHA-II 
(n=8) 
CHF NYHA-IIIb 
Begin (n=8) 
CHF NYHA-IIIb 
End (n=8) 
Age [years] 67±4  54±4 63±3  
Body mass index [kg/cm2] 26.9±0.9  30.6±1.5 26.9±0.9  
Arterial hypertension [n] x   (xx%)  3   (37.5%) 7   (87.5%)  
Diabetes mellitus [n] x   (xx%)  4   (50.0%) 3   (37.5%)  
Active smoking [n] x   (x%)  0   (0%) 0   (0%)  
LV ejection fraction [%] 60±2  26±2 ** 24±2 ** 34±2 
† 
Peak VO2 [ml/kg*min] xx±xx  17.6±1.1 * 14.3±1.2 ** 17.4±1.6 
† 
Etiology of heart failure      
Ischemic heart disease [n] -   -  3   (37.5%) 4   (50.0%)  
Dilative cardiomyopathy [n] -   -  5   (62.5%) 4   (50.0%)  
Cardiovascular medication      
Beta blocker [n] 1   (12.5%)  5   (62.5%) * 7   (87.5%) *  
ACE inhibitor or ATII blocker 3   (37.5%)  8   (100%) * 7   (87.5%) *  
Formatiert: Englisch (USA)
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[n] 
Aldosterone antagonist [n] 0   (0%)  3   (37.5%) * 8   (100%) *  
Lipid profile      
Total cholesterol [mmol/L] 6.4±0.4  6.3±0.3 5.3±0.6 4.7±0.3 
LDL cholesterol [mmol/l] 3.5±0.3  4.3±0.4 3.4±0.5 2.7±0.3 
HDL cholesterol [mmol/L] 1.7±0.3  1.4±0.1 1.1±0.1 *,§ 1.2±0.1 
Data are mean±SEM. Abbreviations: LV: left ventricular; peak VO2: peak oxygen consumption; CHF: chronic heart failure; ACE inhibitor: 
angiotensin converting enzyme inhibitor; ATII blocker: angiotensin II subtype I receptor blocker; LDL: low density lipoprotein; HDL: high 
density lipoprotein. * p<0.05 vs. healthy; ** p<0.001 vs. healthy; § p<0.05 vs. CHF-NYHA-II; † p<0.05 vs. CHF-NYHA-IIIb Beg.  
Material and Methods 
NanoLC-MS/MS analysis 
The proteome of isolated HDL particles from 7 NYHA-IIIb patients and 8 healthy 
controls before and after an ET program were investigated by shotgun LC-MS/MS. In 
total, 4 µg of protein lysates were reduced (2.5 mM DTT for 1 h at 60°C) and alkylated 
(10 mM iodacetamide for 30 min at 37°C). Proteolysis was performed overnight using 
trypsin (Promega, Madison, WI) with a ratio of 1:25 at 37°C. The tryptic digestion was 
stopped by adding acetic acid at the final concentration of 1%, followed by desalting and 
purification using ZipTip-µC18 tips (Millipore, Billerica, MA). 
Proteolytically cleaved peptides (500 ng) were, prior to mass spectrometric analyses, 
enriched on a 2 cm Acclaim PepMap100-precolumn (C18 2 µm, 100 Å) and then 
separated by reverse phase nano HPLC on a 15 cm Acclaim PepMap RSLC-column 
(C18 2 µm, 100 Å) using an Dionex UltiMate 3000 RSLCnano system (Thermo 
Scientific, Waltham, MA) at a constant flow rate of 300 nL/min. Separation was 
achieved using a linear gradient of 60 min (2%-25%) with 0.1% acetic acid, 2% 
acetonitrile in water (solvent A) and 0.1% acetic acid in 100% acetonitrile (solvent B). 
Separated peptides were monitored using a QExactive mass spectrometer (Thermo 
Scientific) equipped with a TriVersa NanoMate ion source (Advion BioSystems, Ithaca, 
NY). The MS-instrument was operated in data-dependent acquisition (DDA) mode. MS 
settings were as follow: survey full-scan spectra were acquired with a resolution R = 
70,000, automated gain control (AGC) target was set to 3e6 ions, the maximum 
injection time was set to 250 ms. MS/MS scan events were repeated for top 10 peaks 
using the higher energy dissociation mode (HCD) at normalized collision induced 
energy of 27.5%, underfill ratio (5%) with an intensity threshold of 8.3e4 ions was 
selected. Already targeted ions for MS/MS were dynamically excluded for 30 s with 
monoisotopic precursor selection enabled. Raw data from the QExactive instrument 
was processed using the Refiner MS 7.5 and Analyst 7.5 module (Genedata, Basel, 
Switzerland). Refiner MS performed peak detection, noise analysis, peak integration, 
isotope grouping and retention time alignment of the LC-MS/MS data. Generated peak 
lists were searched against a human FASTA-formatted database containing 20,268 
unique entries (human_uniprot_swissprot_2011_10.fasta) using an in-house Mascot 
server v2.3.2 (Matrix Science, London, GB). Database searches were performed with 
carbamidomethyl on cysteine as fixed modification and oxidation on methionine as 
variable modification. Enzyme specificity was selected to trypsin with up to two missed 
cleavages allowed using 10 ppm peptide ion tolerance and 20 mmu MS/MS tolerance. 
Only ranked one peptide hits and a Mascot ion score >23 were considered as identified. 
After peak annotation, the data were further processed in Analyst 7.5, where statistical 
data evaluation was performed using univariate and multivariate methods. Paired 
sample T-Test and parametric T-test were used for group comparison. A value of 
p<0.05 was considered as statistically significant. A Principal Components analysis 
(PCA) was applied as classical means of dimensionality reduction and visualization of 
multivariate data. Proteins were functionally assigned to canonical pathways using 
Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, CA, USA). 
 
 
Figure Legends. 
Supplementary figure 1: Correlation analysis between the HDL-induced eNOS 
phosphorylation at Ser
1177
 (A) or change in absolute NO production (B) and the change in 
endothelial function due to the 3 month of exercise intervention.  
 
Table 1: Proteins identified by label free shotgun LC-MS/MS analysis 
Protein 
name  
UNI Prot 
Accesion 
Numbers 
Description 
number of  
identified 
peptides 
control vs. NYHA  
baseline 
control vs. NYHA 
post 
control 
pre vs. post 
NYHA  
pre vs. post 
A1AT P01009 Alpha-1-antitrypsin 22 0.019 (1.77) 0.003 (2.09) 0.087 0.792 
CO3 P01024 Complement C3 17 0.394 0.018 (-0.72) 0.843 0.083 
APOM O95445 Apolipoprotein M 9 0.01 (0.84)  0.006 (0.76) 0.435 0.846 
APOC3 P02656 Apolipoprotein C-III 7 0.001 (-1.45) 0.001 (-1.1) 0.137 0.432 
APOL1 O14791 Apolipoprotein L1 7 0.038 (-0.91) 0.111 0.245 0.87 
APOC4 P55056 Apolipoprotein C-IV 5 0.001 (-1.62) 0.001 (-1.7) 0.644 0.588 
SAA P02735 Serum amyloid A protein 5 0.759 0.007 (-2.3) 0.094 0.287 
CNDP1 Q96KN2* Beta-Ala-His dipeptidase  4 0.606 0.028 (0.75) 0.085 0.844 
CO5 P01031 Complement C5 4 0.033 (-0.85) 0.109 0.841 0.538 
APOC2 P02655 Apolipoprotein C-II 3 0.003 (-0.89) 0.005 (-0.84) 0.004 (0.19) 0.496 
HPTR P00739 Haptoglobin-related protein 3 0.032 (1.67) 0.496 0.382 0.66 
A2MG P01023 Alpha-2-macroglobulin 2 0.365 0.003 (-2.46) 0.088 0.823 
HPT P00738 Haptoglobin 2 0.017 (-1.87) 0.747 0.135 0.304 
PCSK9 Q8NBP7 Proprotein convertase subtilisin/kexin type 9 2 0.072 0.002 (-1.12) 0.63 0.397 
THRB P00734 Prothrombin 2 0.003 (4.97) 0.001 (4.81) 0.228 0.344 
ABCC8 Q09428* ATP-binding cassette sub-family C member 8 1 0.08 0.014 (2.3) 0.532 0.683 
BPIB1 Q8TDL5 BPI fold-containing family B member 1 1 0.089 0.023 (-0.34) 0.296 0.239 
DHX8 Q14562* ATP-dependent RNA helicase DHX8 1 0.017 (2.4) 0.003 (2.89) 0.323 0.549 
HRG P04196 Histidine-rich glycoprotein 1 0.038 (2.11) 0.002 (2.37) 0.202 0.81 
LBP P18428 Lipopolysaccharide-binding protein 1 0.037 (-1.01) 0.002 (-1.52) 0.697 0.207 
SLIT1 O75093* Slit homolog 1 protein  1 0.256 0.042 (-0.83) 0.280 0.325 
* novel identified proteins; group-wise comparison based on independent or dependent (paired) student T-Test. Data were represented by p-Value (effect size) 
